Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

@article{Zeng2010LeadOO,
  title={Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.},
  author={Zhao-Sen Zeng and Yong-hong Liang and Xiao-qing Feng and Fen-er Chen and C Pannecouque and Jan Balzarini and Erik de Clercq},
  journal={ChemMedChem},
  year={2010},
  volume={5 6},
  pages={837-40}
}
Over the past few years, considerable efforts have been devoted to the structural modification of diarylpyrimidines (DAPYs), a family of non-nucleoside reverse transcriptase inhibitors (NNRTIs) with remarkable anti-HIV-1 activity, leading to the development of etravirine (1), rilpivirine (TMC278, 2) and other highly potent compounds against both wild type and mutant strains of HIV-1 reverse transcriptase (RT). 

From This Paper

Figures and tables from this paper.

References

Publications referenced by this paper.

Chem

B. L. De Corte, J. Med
2005, 48, 1689 – • 1696

Similar Papers

Loading similar papers…